Addex Therapeutics Ltd (ADR) ((ADXN)) has held its Q3 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Addex Therapeutics Ltd (ADR) recently held its earnings call, highlighting a mix of optimism and challenges. The company showcased significant progress in key programs and strategic collaborations, which are positive indicators for future growth. However, the need for additional funding for unpartnered programs and stable but limited income suggest challenges in financial sustainability.
Progress in GABAB PAM and Dipraglurant Programs
Addex Therapeutics has made excellent strides in its GABAB PAM program for chronic cough and dipraglurant post-stroke recovery. The company successfully completed preclinical characterization and IND-enabling studies, marking a critical step forward in these initiatives.
Strategic Collaborations and Investments
The company’s strategic collaborations are a key highlight, with partner Indivior completing IND-enabling studies for a substance use disorders drug candidate. Additionally, Addex’s investment in Stalicla is advancing patient stratification studies in autism, with ongoing discussions for broader applications with pharmaceutical companies.
Strong Cash Position
Addex ended Q3 2025 with CHF 2.2 million in cash, providing a financial runway through mid-2026. This strong cash position is bolstered by a significant reduction in cash burn following the Neurosterix spinout transaction.
Limited Funding for Unpartnered Programs
Despite a solid cash position, the current funds do not support the progression of unpartnered programs into the clinic, indicating a potential gap in financing for further development.
Stable but Limited Income
The company’s income in Q3 2025 was CHF 0.1 million, primarily from patent maintenance licensed to Indivior. This reflects a stable yet limited growth in revenue streams, similar to the previous year.
Forward-Looking Guidance
During the earnings call, Addex provided significant forward-looking guidance. The company emphasized progress in their GABAB PAM program, with eligibility for up to USD 330 million in milestone payments from Indivior. They also highlighted advancements in the dipraglurant post-stroke recovery program, aiming to meet the needs of over 100 million stroke survivors. Financially, Addex assured liquidity through mid-2026, although unpartnered programs remain unfunded. Investments in Neurosterix and Stalicla were also discussed, alongside stable R&D and G&A expenses.
In summary, Addex Therapeutics Ltd (ADR) presented a mixed outlook during their earnings call. While significant progress and strategic collaborations indicate potential for future growth, financial sustainability remains a challenge due to limited funding for unpartnered programs and stable but modest income. The company’s forward-looking guidance, however, provides a roadmap for potential milestones and continued development.